|Bid||46.78 x 2900|
|Ask||46.84 x 1100|
|Day's range||46.79 - 47.54|
|52-week range||44.30 - 63.69|
|Beta (3Y monthly)||0.85|
|PE ratio (TTM)||14.91|
|Forward dividend & yield||1.64 (3.53%)|
|1y target est||N/A|
Key highlights of the week include Merck's (MRK) offer to buy private cancer biotech and AbbVie (ABBV) and Lilly's (LLY) updates from clinical studies.
Synlogic (SYBX) announces clinical collaboration with Roche to develop its pre-clinical cancer candidate in combination with Roche's PD-L1 inhibitor, Tecentriq.
Novartis (NVS) reports encouraging data on combination asthma drug. The company also highlights its growth plans at its annual meet.
Array BioPharma's (ARRY) phase III study, evaluating the Braftovi triplet for treating metastatic colorectal cancer, meets the primary goal of ORR and OS. Shares rally.
Merck (MRK) signs a definitive agreement to buy small private biotech, Peloton Therapeutics for $1.05 billion in cash to boost its oncology pipeline.
Ted Samuels paid $236,440 for 5,000 shares last week. It’s the first open-market purchase of Bristol-Myers stock by an insider in a year.
The spending by the industry’s main trade group and seven key drugmakers has climbed to a level not seen in a decade.
A stormy honeymoon could be in the offing following the biggest pharmaceutical acquisition in history, according to one analyst.
Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.
Zacks.com featured highlights include: BlackRock, Northrop, Progressive, Interpublic Group and Bristol-Myers
AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Nektar's (NKTR) earnings and sales beat estimates in the first quarter. The company is progressing well with its pipeline candidates.
Zacks.com featured highlights include: Exantas Capital, Lamb Weston, Bristol-Myers Squibb, Amedisys and Computer Programs and Systems
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.